Mitra’s CANScript validated for personalized cancer care

The article ‘Predicting clinical response to anti-cancer drugs using an ex vivo platform that captures tumor heterogeneity' was published in Nature Communications on February 27, 2015

56756756765

(Photo Courtesy: www.latestnewslink.com)

Mitra Biotech, a cancer diagnostics company, announced that a study validating its flagship platform CANScript has been published in Nature Communications, an open access, multidisciplinary journal dedicated to publishing high-quality research in all areas of the biological, physical, chemical and earth sciences.

Papers published by the journal represent important advances of significance to specialists within each field.

The article ‘Predicting clinical response to anti-cancer drugs using an ex vivo platform that captures tumor heterogeneity' was published in Nature Communications on February 27, 2015.

"The study is the first of its kind in delineating the importance of capturing tumor heterogeneity to elicit accurate prediction of clinical response," said Dr Leena Gandhi, one of leading oncologists and investigator at Dana Farber Cancer Institute at Boston, who is not associated with the study.

"This platform would not only be beneficial in enabling physicians to select the right mode of treatment, but also speed-up oncology drug development, thereby reducing go-to market time and costs," she added.

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X